303 related articles for article (PubMed ID: 17951083)
1. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.
de Bont JM; Vanderstichele H; Reddingius RE; Pieters R; van Gool SW
Eur J Paediatr Neurol; 2008 Jul; 12(4):334-41. PubMed ID: 17951083
[TBL] [Abstract][Full Text] [Related]
2. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid.
Talab R; Valis M; Rehak S; Krejsek J
Neuro Endocrinol Lett; 2009; 30(5):647-51. PubMed ID: 20035270
[TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.
Agren-Wilsson A; Lekman A; Sjöberg W; Rosengren L; Blennow K; Bergenheim AT; Malm J
Acta Neurol Scand; 2007 Nov; 116(5):333-9. PubMed ID: 17922727
[TBL] [Abstract][Full Text] [Related]
6. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid cleaved-tau protein and 9-hydroxyoctadecadienoic acid concentrations in pediatric patients with hydrocephalus.
Cengiz P; Zemlan F; Ellenbogen R; Hawkins D; Zimmerman JJ
Pediatr Crit Care Med; 2008 Sep; 9(5):524-9. PubMed ID: 18679140
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
9. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.
Valis M; Talab R; Stourac P; Andrys C; Masopust J
Neuro Endocrinol Lett; 2008 Dec; 29(6):971-6. PubMed ID: 19112391
[TBL] [Abstract][Full Text] [Related]
10. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP
Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581
[TBL] [Abstract][Full Text] [Related]
12. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.
Brew BJ; Pemberton L; Blennow K; Wallin A; Hagberg L
Neurology; 2005 Nov; 65(9):1490-2. PubMed ID: 16275845
[TBL] [Abstract][Full Text] [Related]
13. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).
Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J
Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
15. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
16. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
17. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls.
Pijnenburg YA; Janssen JC; Schoonenboom NS; Petzold A; Mulder C; Stigbrand T; Norgren N; Heijst H; Hack CE; Scheltens P; Teunissen CE
Dement Geriatr Cogn Disord; 2007; 23(4):225-30. PubMed ID: 17290105
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
19. The relationship between cerebrospinal fluid biomarkers and depression in elderly women.
Gudmundsson P; Skoog I; Waern M; Blennow K; Pálsson S; Rosengren L; Gustafson D
Am J Geriatr Psychiatry; 2007 Oct; 15(10):832-8. PubMed ID: 17911361
[TBL] [Abstract][Full Text] [Related]
20. [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker].
Urakami K; Nakashima K
Rinsho Shinkeigaku; 2002 Nov; 42(11):1162-4. PubMed ID: 12784694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
